関連する実験動画

Updated: Aug 20, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

慢性骨髄性白血病におけるablおよびbcr遺伝子の融合転写

E Shtivelman, B Lifshitz, R P Gale

|June 13, 1985

まとめ

慢性骨髄性白血病 (CML) は,染色体転位が合併遺伝子を生成することを含む. この遺伝子は8基塩基RNAを産生し,がんプロセスを駆動するタンパク質である可能性が高い.

科学分野:

腫瘍学腫瘍学
分子生物学は分子生物学である.
遺伝学遺伝学とは

背景:

人間の慢性骨髄性白血病 (CML) は,特定の染色体異常と関連しています.
この異常は,染色体9と22の相互転位によるものです.

研究の目的:

CML特異的な染色体転位に関連したRNAトランスクリプトを特徴付けるために.
CMLにおける悪性プロセスの分子基盤を調査する.

主な方法:

慢性骨髄性白血病に特異的なRNAの分析.
8キロベースRNA分子の特徴.

主要な成果:

CMLに特異的な8キロ塩基RNAが特定されました.
このRNAは,abl腫瘍遺伝子とbcr遺伝子の転位から生じる融合トランスクリプトである.

結論:

特定された融合RNAトランスクリプトは,CMLにおける重要な分子マーカーである.
その結果生成される溶融タンパク質は,慢性骨髄性白血病の病原性に関与している.

さらに関連する動画

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

関連する概念動画

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...